KARFİLZOMİB-SİKLOFOSFAMİD-DEKSAMETAZON (KCD) PROTOKOLÜ

Kaynaklar:

1- Avet-Loiseau H, Fonseca R, Siegel D, et al. . Carfilzomib significantly improves the progression- free survival of high-risk patients in multiple myeloma. Blood. 2016;128(9):1174-1180.

2- Bringhen S, Petrucci MT, Larocca A, et al. . Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63-69.

3- Sonneveld P, Avet-Loiseau H, Lonial S, et al. . Treatment of multiple myeloma with highrisk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962.

4-Mateos, M-V, Ocio, EM, Sureda Balari, A, et al. Randomized phase 2 study of weekly carfilzomib 70 Mg/m2 and dexamethasone plus/minus cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) patients (GEM-KyCyDex). Blood 2020; 136.

5-Kumar, S, Fu, A, Niesvizky, R, et al. Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. Blood Adv 2021; 5: 367–376.

6-Gandhi, UH, Cornell, RF, Lakshman, A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 2019; 33: 2266–2275.